GenScript ProBio signed a memorandum of understanding with DAAN Bio Therapeutics to cooperate to discover and develop innovative drugs on Thursday.

Through this MOU, GenScript ProBio and DAAN agreed to strengthen their cooperation, specifically in the cell and gene therapy (CGT) and biologics field.

The two companies will collaborate in the overall development process, including discovery, manufacturing, and clinical trials of antibody and cell treatments and related research and service projects.

DAAN has conducted single-cell transcriptomic and proteomic biomarker analysis through its analysis platform using tissues secured from solid cancer patients along with DAAN Cancer Research Institute and Yonsei New Il Han Institute for Integrative Cancer Research.

DAAN signed a contract manufacturing organization (CMO) service agreement through GenScript ProBio to develop antibodies that bind to the discovered target and establish its own bispecific antibody production pipeline using antibodies derived through good manufacturing practice (GMP) production.

“We hope this strategic partnership with DAAN Bio Therapeutics will provide us with the global support required to accelerate the development of DAAN’s antibody and cell therapy through GenScript ProBio’s one-stop CDMO service platform.” CEO Brian H. Min of GenScript ProBio said.

DAAN Bio Therapeutics Co-Founder & CEO Cho Byoung-chul said, “This strategic cooperation will be an opportunity to revitalize the development of antibody and cell therapy that control unique cancer treatment targets already secured by our company using GenScript ProBio’s qualified and competitive technologies.”

GenScript ProBio and DAAN Bio Therapeutics said they would continue working closely to develop other pipelines of DAAN Bio Therapeutics, including antibody-drug and cell therapy.